Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.54 -1.3%	$1.60	$1.03 ▼ $2.41	$48.04M	-0.53	429,811 shs	99,202 shs
ELYM Eliem Therapeutics	$1.70 +17.2%	$1.36	$2.35 ▼ $11.55	$50.58M	-0.39	486,688 shs	4.70 million shs
PYRGF PyroGenesis Canada	$0.28 -0.2%	$0.33	$0.25 ▼ $0.71	$52.45M	0.83	12,768 shs	39,309 shs
TTPH Tetraphase Pharmaceuticals	$2.20	$2.20	$0.56 ▼ $8.60	$15.98M	2.33	932,542 shs	282,689 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-1.28%	-4.35%	-2.53%	+4.05%	-26.14%
ELYM Eliem Therapeutics	0.00%	+12.58%	+32.81%	+42.86%	-71.90%
PYRGF PyroGenesis Canada	-0.21%	-1.10%	-19.89%	-13.85%	-47.66%
TTPH Tetraphase Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.0555 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.0	0.6
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.3301 of 5 stars	0.0	4.0	0.0	0.0	0.0	1.7	0.0
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	192.21% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TTPH, PYRGF, ELYM, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	5.74	N/A	N/A	($0.01) per share	-28.00
TTPH Tetraphase Pharmaceuticals	$7.38M	2.17	N/A	N/A	$6.68 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.47	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.01	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
TTPH Tetraphase Pharmaceuticals	-$70.08M	-$22.85	N/A	N/A	N/A	-798.18%	-210.86%	-121.73%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
ELYM Eliem Therapeutics	N/A	60.41	60.41
PYRGF PyroGenesis Canada	N/A	0.60	0.50
TTPH Tetraphase Pharmaceuticals	0.06	3.66	3.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
ELYM Eliem Therapeutics	69.76%
PYRGF PyroGenesis Canada	0.03%
TTPH Tetraphase Pharmaceuticals	42.29%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
ELYM Eliem Therapeutics	4.70%
PYRGF PyroGenesis Canada	47.68%
TTPH Tetraphase Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
PYRGF PyroGenesis Canada	90	187.31 million	96.34 million	No Data
TTPH Tetraphase Pharmaceuticals	119	7.26 million	N/A	Optionable

TTPH, PYRGF, ELYM, and ATNM Headlines

Recent News About These Companies

NAFDAC Seeks More Synergy with Indian Pharmaceutical Sector

March 12, 2023 | thisdaylive.comT

Infinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News Summary

February 26, 2023 | benzinga.com

Tetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test Results

August 30, 2022 | thestreet.com

Tetraphase Executive Profits Hours Before Stock Plummets

August 20, 2022 | thestreet.com

TTPH_old Historical Data

April 4, 2022 | investing.com

10 Worst NASDAQ Biotech Stocks in the Third Quarter

January 16, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTPH, PYRGF, ELYM, and ATNM Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.54 -0.02 (-1.28%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.54 +0.00 (+0.32%)

As of 08/8/2025 05:16 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Eliem Therapeutics NASDAQ:ELYM

$1.70 +0.25 (+17.24%)

As of 08/4/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

PyroGenesis Canada NASDAQ:PYRGF

$0.28 0.00 (-0.21%)

As of 08/8/2025 02:54 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Tetraphase Pharmaceuticals NASDAQ:TTPH

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time